{
    "clinical_study": {
        "@rank": "1416", 
        "arm_group": [
            {
                "arm_group_label": "QAW039 + Montelukast", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "QAW039 Once a day (q.d.)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "QAW039 Twice a day (b.i.d.)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Montelukast", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of QAW039 alone and in combination with\n      Montelukast in patients with allergic rhinitis (hay fever) using an environmental exposure\n      chamber."
        }, 
        "brief_title": "A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 18-65 years inclusive, with a clinical history of intermittent\n             allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during\n             each of the last two grass pollen allergy seasons.\n\n          -  A positive skin prick test at Visit 1 to dactylis glomerata with a wheal diameter\n             equal to or greater than 3 mm and a negative control with a wheal diameter of zero. A\n             positive skin prick test within 12 months prior to Visit 1 is also acceptable.\n\n          -  FEV1 measured by spirometry must be \u226580% of their predicted value at screening. If\n             the patient does not achieve \u226580% of their predicted value this may be repeated prior\n             to the EEC challenge at visit 2.\n\n          -  TNSS score \u22656 on at least one assessment during the 2h EEC challenge at Screening.\n\n        Exclusion Criteria:\n\n          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of enrollment, whichever is longer; or longer if required by local\n             regulations, and for any other limitation of participation in an investigational\n             trial based on local regulations.\n\n          -  Pregnant or nursing (lactating) women,\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, unless they are using effective methods of contraception during\n             dosing of study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "188", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804400", 
            "org_study_id": "CQAW039A2212", 
            "secondary_id": "2012-001389-14"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "QAW039 + Montelukast", 
                    "QAW039 Once a day (q.d.)", 
                    "QAW039 Twice a day (b.i.d.)"
                ], 
                "intervention_name": "QAW039", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "QAW039 + Montelukast", 
                    "Montelukast"
                ], 
                "intervention_name": "Montelukast", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "QAW039 + Montelukast", 
                    "QAW039 Once a day (q.d.)", 
                    "QAW039 Twice a day (b.i.d.)", 
                    "Montelukast", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Montelukast"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hannover", 
                    "country": "Germany", 
                    "zip": "30625"
                }, 
                "name": "Novartis Investigative Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Total Nasal Symptom Score (TNSS) averaged over the last two hours (2-4h) of exposure following 14 days treatment with QAW039 and/or Montelukast or matched placebo", 
            "measure": "Change in Total Nasal Symptom Score from baseline at 14 days", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804400"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total Ocular Symptom Score (TOSS), defined as the sum of ocular symptoms of eye tearing, itching, watery eyes and redness, each of which is scored on a scale from 0 and 3", 
                "measure": "Change in Total Ocular Symptom score from Baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Measured using rhinomanometry Flow rates at 150 Pa will be obtained separately for the right and left nostrils (cm^3/second). The sum of the flow rates of both nostrils will be calculated from the two measurements", 
                "measure": "Change in Nasal Flow from baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Prior to, and every 60 min during allergen exposure period"
            }, 
            {
                "description": "Total weight of tissues (before and after use)", 
                "measure": "Change in Nasal excretion weight from baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Change in FEV1 from Baseline", 
                "measure": "Change in Forced Expiratory Volume in 1 Second (FEV1) from baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Change in FVC from Baseline", 
                "measure": "Change in Forced Vital Capacity (FVC) from baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Change in FEV1/FVC from Baseline", 
                "measure": "Change in FEV1/FVC at from baseline at 14 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Determined at steady state in plasma", 
                "measure": "Plasma Concentration maximum (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }, 
            {
                "description": "Determined at steady state in plasma", 
                "measure": "Plasma Concentration Minimum (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }, 
            {
                "description": "Determined at steady state in plasma", 
                "measure": "Plasma Concentration Average (Cav)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }, 
            {
                "description": "Determined at steady state in plasma", 
                "measure": "Time of Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }, 
            {
                "description": "Determined at steady state in plasma", 
                "measure": "Area Under Curve (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}